Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan
Journal of Gastroenterology and Hepatology · 2023
DOI: 10.1111/jgh.16246 ↗At a glance
Multizentrische Studie in Journal of Gastroenterology and Hepatology, 2023. Written by Koji Yokoyama and 13 co-authors. Institution: Department of Pediatrics, Jichi Medical University School of Medicine, Tochigi, Japan. Major MEDLINE topics: Colitis, Ulcerative, Biological Products. Cited 14 times so far (Crossref); 23 references. Funded by: Japanese Society for Pediatric Inflammatory Bowel Disease.
Abstract (original language)
Background
Vedolizumab (VDZ) is a humanized monoclonal antibody that binds to α4β7 integrin expressed in T‐lymphocytes and is gut selective. Few studies have evaluated the safety and efficacy of VDZ in pediatric ulcerative colitis (UC) patients, especially from Asia.
Methods
A longitudinal multicenter retrospective study was conducted at 10 Japanese tertiary medical institutions. Patients aged ≤18 years old who received VDZ for UC between January 2019 and July 2021 were enrolled. Information on the clinical characteristics, prior/concomitant treatment, and safety during the observation period was collected.
Results
The data obtained from 48 patients (males, n = 30; females, n = 18) were analyzed. The median age at VDZ induction was 14 (range 4–18) years old. VDZ was indicated in 73% of patients as switching from previous biologics due to primary failure, loss of response, and adverse events (AEs) and was the first biologic in 27%. Remission was achieved or maintained at weeks 14, 30, and 54 in 79.2%, 75.0%, and 65.8% of patients, respectively. There were no significant differences between the number of previous biologics exposures and VDZ effectiveness. The hematocrit, serum albumin concentrations, and erythrocyte sedimentation rate (ESR) at baseline differed significantly by VDZ effectiveness. Nine AEs, including infusion reaction, were noted in seven (14.3%) patients. There were no severe AEs related to VDZ administration.
Conclusions
VDZ was safe and effective in children with UC. The hematocrit, albumin, and ESR at VDZ initiation might be predictors for VDZ effectiveness. VDZ may be an important option for pediatric patients and can be used as an alternative to immunomodulators.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics, Jichi Medical University School of Medicine, Tochigi, Japan.
- Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
- Department of Gastroenterology and Endocrinology, Osaka Women's and Children's Hospital, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Miyagi Children's Hospital, Sendai, Japan.
- Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan.
ORCID profiles: Koji Yokoyama, Ryusuke Nambu, Tatsuki Mizuochi, Takahiro Kudo, Itaru Iwama, Katsuhiro Arai
Funding
- Japanese Society for Pediatric Inflammatory Bowel Disease
Cite
APA
Yokoyama, K., Yamamoto, Y., Nambu, R., Hagiwara, S. I., Abukawa, D., Mizuochi, T., Kudo, T., Sado, T., Iwata, N., Ishige, T., Iwama, I., Kumagai, H., Arai, K., & Shimizu, T. (2023). Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16246
Vancouver
Yokoyama K, Yamamoto Y, Nambu R, Hagiwara SI, Abukawa D, Mizuochi T, et al. Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16246
BibTeX
@article{Yokoyama2023,
author = {Yokoyama, Koji and Yamamoto, Yoko and Nambu, Ryusuke and Hagiwara, Shin-Ichiro and Abukawa, Daiki and Mizuochi, Tatsuki and Kudo, Takahiro and Sado, Tomomitsu and Iwata, Naomi and Ishige, Takashi and Iwama, Itaru and Kumagai, Hideki and Arai, Katsuhiro and Shimizu, Toshiaki},
title = {Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan},
journal = {Journal of Gastroenterology and Hepatology},
year = {2023},
doi = {10.1111/jgh.16246}
}
EUVIMED